I. COMMENCED TRADING IN MARCH | ||||||||
Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Gross |
Post- |
INITIAL OFFERINGS | ||||||||
Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA)1 |
11/6/12 |
3/21/13 |
4.6S |
$14 |
17.44 |
J.P. Morgan |
$64.4 |
$244.16 |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH)2 |
2/11/13 |
3/20/13 |
10.7S |
$7 |
19.9 |
Barclays |
$75 |
$139.3 |
|
Total: $139.4M Number of IPOs in March: 2 Average value of March IPOs: $69.7M Number of IPOs in 2013: 4 Total raised in IPOs in 2013: $247.6M Average value of IPOs in 2013: $61.9M | ||||||||
Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Gross |
Post- |
FOLLOW-ON OFFERINGS | ||||||||
Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN)3 |
11/21/12 |
3/1/13 |
16.9S |
$8.40 |
96.6 |
Citigroup |
$141.96 |
$811.4 |
Cerus Corp. (Concord, Calif.; CERS)4 |
1/10/12 |
3/14/13 |
8.3S |
$4.20 |
64.59 |
Cowen & Co. |
$35 |
$271.3 |
Cynapsus Therapeutics Inc. (Toronto; TSX-V:CTH) |
3/1/13 |
3/18/13 |
15.9U |
C46 |
N/A |
M Partners Inc. |
C$7.3 ($7.14) |
N/A |
Hyperion Therapeutics Inc. (South San Francisco; HPTX)5 |
3/8/13 |
3/8/13 |
3.23S |
$20.75 |
19.95 |
Leerink Swann |
$67 |
$413.96 |
Imprimis Pharmaceuticals Inc. (Solana Beach, Calif.; IMMY)6 |
2/11/13 |
3/14/13 |
0.276S |
$5.25 |
8.876 |
MDB Capital Group |
$1.45 (overallotment option) |
$46.6 |
Inovio Pharmaceuticals Inc. (Blue Bell, Pa.; NYSE:INO) |
9/2/11 |
3/7/13 |
27.38S and W for 13.69S |
$0.55 |
179.9 |
Cowen & Co. |
$15.06 |
$98.945 |
Medgenics Inc. (San Francisco; MDGN)7 |
10/26/12 |
3/26/13 |
6.07S and Series 2013-A W for 3.22S |
$5.25 |
18.37 |
Maxim Group LLC |
$31.87 |
$96.4 |
Oculus Innovative Sciences Inc. (Petaluma, Calif.; OCLS)8 |
5/3/11 |
3/7/13 |
8.625S |
$0.40 |
46.09 |
Aegis Capital Corp. |
$3.45 |
$18.436 |
Pharmacyclics Inc. (Sunnyvale, Calif.; PCYC)9 |
3/7/13 |
3/8/13 |
2.2S |
$94.20 |
72.4 |
J.P. Morgan |
$207.24 |
$6.82B |
Stem Cell Therapeutics Corp. (Toronto; TSX-V:SSS) |
3/7/13 |
3/7/13 |
1.3U |
C$0.25 |
N/A |
Euro Pacific Canada Inc. |
C$3.1 ($3) |
N/A |
Tesaro Inc. (Waltham, Mass.; TSRO)10 |
2/27/13 |
3/1/13 |
5.4S |
$18 |
32.57 |
Citigroup |
$22.2 ($97.2 total raised) |
$586.26 |
|
Total: $608.92M Number of follow-on offerings in March: 10 Average value of March follow-ons: $60.89M Number of follow-on offerings in 2013: 32 Total raised in follow-ons in 2013: $3,001.2M Average value of follow-ons in 2013: $93.79M | ||||||||
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. NYSE = New York Stock Exchange. TSX-V = Toronto Stock Venture Exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. 1 Enanta's overallotment option: 600,000 shares. 2 Tetraphase's overallotment option: 1.6M shares. 3 Includes Achillion's overallotment option: 1.9M shares. 4 Cerus' overallotment option: 1.25M shares. 5 Includes Hyperion's overallotment option: 431,250 shares. 6 Imprimis' underwriters exercised the overallotment option, bringing the total shares offered to 2.1M shares and the total amount raised to $ 11.11M. 7 Medgenics completed the overallotment option of its February public offering., bringing the total to $31.87M. 8 Includes Oculus' overallotment option: 1.125M shares. 9 Pharmacyclics' overallotment option: 330,000 shares. 10 Includes Tesaro's overallotment option: 708,000 shares. | ||||||||
II. FILED AND PENDING | ||||||
Company |
Date Filed |
Shares/Units (M) |
Price |
Shares Out |
Lead, Other Underwriters |
Gross (US$M) |
INITIAL OFFERINGS | ||||||
Alcobra Ltd. (Tel Aviv, Israel; ADHD)1 |
3/19/13 |
1.365S |
$10-$12 |
9.25 |
Aegis Capital Corp. |
$15 |
Ambit Biosciences Inc. (San Diego; AMBI) |
2/20/13 |
N/A |
N/A |
N/A |
Citigroup |
$86.25 |
Audeo Oncology Inc. (San Francisco; AURX)2 |
7/6/12 |
3.25S |
$14-$16 |
10.8 |
Leerink Swann |
$49 |
Chimerix Inc. (Research Triangle Park, N.C.; CMRX)3 |
3/8/13 |
6.1S |
$13-$15 |
23.19 |
Morgan Stanley |
$85.4 |
Globeimmune Inc. (Louisville, Colo.; GBIM) |
7/2/12 |
5S |
$11-$13 |
17.23 |
Wells Fargo Securities |
$60 |
GW Pharma plc (Porton Down, UK; GWPH) |
3/19/13 |
ADSs |
N/A |
N/A |
Lazard Capital Markets |
$50 |
Omthera Pharmaceuticals Inc. (Princeton, N.J.; OMTH)4 |
3/8/13 |
5.775S |
$12-$14 |
21.12 |
BofA Merrill Lynch |
$75.075 |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) |
5/11/12 |
N/A |
N/A |
N/A |
Jefferies |
$115 |
Paratek Pharmaceuticals Inc. (Boston; PRTK) |
9/27/12 |
N/A |
N/A |
N/A |
UBS Investment Bank |
$92 |
Sophiris Bio Inc. (San Diego; SPHS) |
2/15/13 |
N/A |
N/A |
N/A |
Citigroup |
$74.75 |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. General shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. 1 Alcobra's overallotment option: 204,750. 2 Audeo's overallotment option: 487,500-shares. 3 Chimerix's overallotment option: 915,000 shares. 4 Omthera's overallotment option: 866,250 shares. | ||||||